Senisca
Develops RNA-based therapies targeting cellular ageing for patients with age-related diseases
Highlights
- New on EvolcAdded 2026-11-13
About Senisca
Senisca is a University of Exeter spinout biotech developing oligonucleotide-based therapeutics that modulate RNA splicing to reprogram senescent cells for the treatment of age-related disease.
The company was founded in 2020 and is headquartered in Exeter, United Kingdom. Its founders' research identified dysregulated RNA splicing as a contributor to cellular senescence; Senisca reports raising private equity and public grant funding.
Product: Oligonucleotide-based therapeutic approaches that modulate RNA splicing and reprogram senescent cells.
Jobs at Senisca
More biotech & pharma companies
SENTINAL4D
AI models and imaging data tools for biotech and pharmaceutical R&D teams studying cell morphology and drug responsesYoung companyNew on EvolcSequoia Genetics
Human genetics research and analysis for pharma, biotech, investors, and academic institutions developing medicinesYoung companyNew on EvolcSeren Plus
Wholesale supplier of prescription medicines and aesthetic products to pharmacies and clinics across the UKShafi Consultancy
Clinical trial statistical programming and data services for pharmaceutical companies and contract research organizationsNew on EvolcSiinovia (UK)
Develops and distributes niche generic and value-added medicines for healthcare markets and pharmaceutical partnersNew on EvolcSimplex Molecular
Molecular biology R&D, assay development and testing for research teams and businessesYoung companyNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content management
- Craft CMSHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-powered-by
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.